_{Niraparib，又称尼拉帕尼，是可口服的PARP抑制剂，作用于PARP1/2的IC50值约为3.8 nM和2.1 nM，能够抑制DNA修复，具有抗肿瘤活性，临床上可用于治疗复发性上皮卵巢癌、输卵管癌和原发性腹膜癌。}

参考文献

[1] Jones P, Altamura S, Boueres J, et al. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009 Nov 26;52(22):7170-85. doi: 10.1021/jm901188v(IF:6.054).

[2] Wang L, Mason KA, Ang KK, et, al. MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs. 2012 Dec;30(6):2113-20. doi: 10.1007/s10637-011-9770-x(IF:2.663).

-25~-15℃保存，有效期3年。